. . "Idiotypick\u00E9 (Id) proteinov\u00E9 struktury monoklon\u00E1ln\u00EDho imunoglobulinu produkovan\u00E9ho malign\u00EDmi bu\u0148kami mnoho\u010Detn\u00E9ho myelomu jsou exprimov\u00E1ny na bun\u011B\u010Dn\u00E9m povrchu myelomov\u00FDch plazmatick\u00FDch bun\u011Bk a daj\u00ED se vyu\u017E\u00EDt pro indukci n\u00E1dorov\u011B specifick\u00FDch T lymfocyt\u016F. Jsou p\u0159edkl\u00E1d\u00E1ny imunitn\u00EDmu syst\u00E9mu jako vysoce specifick\u00FD antigen asociovan\u00FD s n\u00E1dorem. Vznikl\u00E1 humor\u00E1ln\u00ED i celul\u00E1rn\u00ED anti-idiotypick\u00E1 odpov\u011B\u010F pak kontroluje r\u016Fst myelomov\u00E9ho klonu. Vakcinace Id-proteinem je jednou z mo\u017Enost\u00ED imunoterapie mnoho\u010Detn\u00E9ho myelomu a jin\u00FDch B-bun\u011B\u010Dn\u00FDch malignit, s c\u00EDlem vyvolat specifickou imunitn\u00ED odpov\u011B\u010F proti n\u00E1dorov\u00FDm bu\u0148k\u00E1m. Id-protein se vyu\u017E\u00EDv\u00E1 pro bezbun\u011B\u010Dn\u00E9 vakc\u00EDny, kde se pod\u00E1v\u00E1 samotn\u00FD nebo s vhodn\u00FDm adjuvans, a pro vakc\u00EDny bun\u011B\u010Dn\u00E9, ve kter\u00FDch se pod\u00E1vaj\u00ED Id-protein exprimuj\u00EDc\u00ED dendritick\u00E9 bu\u0148ky. N\u00E1\u0161 p\u0159ehledn\u00FD \u010Dl\u00E1nek shrnuje preklinick\u00E9 a klinick\u00E9 v\u00FDsledky Id-specifick\u00FDch vakcinac\u00ED u mnoho\u010Detn\u00E9ho myelomu." . . "1"^^ . "CZ - \u010Cesk\u00E1 republika" . . . "Vakc\u00EDny v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu."@cs . . "Vakc\u00EDny v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu." . . . . "Vaccines in the treatment of multiple myeloma."@en . . "Vaccines in the treatment of multiple myeloma."@en . "Klinick\u00E1 onkologie" . "2002" . "multiple myeloma; vaccination; immunotherapy; dendritic cells; idiotype"@en . . "Idiotypick\u00E9 (Id) proteinov\u00E9 struktury monoklon\u00E1ln\u00EDho imunoglobulinu produkovan\u00E9ho malign\u00EDmi bu\u0148kami mnoho\u010Detn\u00E9ho myelomu jsou exprimov\u00E1ny na bun\u011B\u010Dn\u00E9m povrchu myelomov\u00FDch plazmatick\u00FDch bun\u011Bk a daj\u00ED se vyu\u017E\u00EDt pro indukci n\u00E1dorov\u011B specifick\u00FDch T lymfocyt\u016F. Jsou p\u0159edkl\u00E1d\u00E1ny imunitn\u00EDmu syst\u00E9mu jako vysoce specifick\u00FD antigen asociovan\u00FD s n\u00E1dorem. Vznikl\u00E1 humor\u00E1ln\u00ED i celul\u00E1rn\u00ED anti-idiotypick\u00E1 odpov\u011B\u010F pak kontroluje r\u016Fst myelomov\u00E9ho klonu. Vakcinace Id-proteinem je jednou z mo\u017Enost\u00ED imunoterapie mnoho\u010Detn\u00E9ho myelomu a jin\u00FDch B-bun\u011B\u010Dn\u00FDch malignit, s c\u00EDlem vyvolat specifickou imunitn\u00ED odpov\u011B\u010F proti n\u00E1dorov\u00FDm bu\u0148k\u00E1m. Id-protein se vyu\u017E\u00EDv\u00E1 pro bezbun\u011B\u010Dn\u00E9 vakc\u00EDny, kde se pod\u00E1v\u00E1 samotn\u00FD nebo s vhodn\u00FDm adjuvans, a pro vakc\u00EDny bun\u011B\u010Dn\u00E9, ve kter\u00FDch se pod\u00E1vaj\u00ED Id-protein exprimuj\u00EDc\u00ED dendritick\u00E9 bu\u0148ky. N\u00E1\u0161 p\u0159ehledn\u00FD \u010Dl\u00E1nek shrnuje preklinick\u00E9 a klinick\u00E9 v\u00FDsledky Id-specifick\u00FDch vakcinac\u00ED u mnoho\u010Detn\u00E9ho myelomu."@cs . . . "14110" . . . "0862-495X" . . "[945BC27F3ECB]" . "44-47" . "4"^^ . "Vakc\u00EDny v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu." . "P(GA301/00/0405)" . "RIV/00216224:14110/02:00007788!RIV08-GA0-14110___" . "B\u00FCchler, Tom\u00E1\u0161" . "Vakc\u00EDny v l\u00E9\u010Db\u011B mnoho\u010Detn\u00E9ho myelomu."@cs . . "4"^^ . "Suplement" . "Musilov\u00E1, Romana" . "RIV/00216224:14110/02:00007788" . "Kov\u00E1\u0159ov\u00E1, Lucie" . "Malignant cells in multiple myeloma produce a monoclonal immunoglobulin which is tumor-specific and can be used for the induction of T lymphocytes. Idiotypic (Id) structures are expressed at the cell surface of malignant plasma cells and allow the recognition and targeting of these cells by Id-specific T lymphocytes. The induced humoral and cellular immune response controls the growth of the malignant cell clone. Vaccination using Id-protein has been attempted in patients with multiple myeloma and other B cell malignancies. The aim of this therapy is to induce specific immune response directed against the tumor cells. Id-protein may be used for cell-free vaccines where it is administered alone or after conjugation with a suitable adjuvans, and for cellular vaccines where it is loaded into dendritic cells. We review preclinical and clinical results of Id-specific vaccinations for multiple myeloma."@en . "668363" . "H\u00E1jek, Roman" .